According to filings with the U.S. Securities and Exchange Commission, Entact Bio is raising up to $39,899,999.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Victoria Richon played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Entact Bio
Entact Bio is a preclinical stage biotechnology company developing a new class of drugs that enhance the function of beneficial proteins. Launched by a founding team deeply rooted in deubiquitinase (DUB) biochemistry, chemical biology, disease biology, and small-molecule drug development, Entact has designed its proprietary Encompass platform to create enhancement-targeting chimeric (ENTAC) medicines. ENTACs harness the ability of DUBs to regulate proteins. By leveraging this natural cellular mechanism to enhance protein function, Entact is expanding the universe of treatable diseases.

To learn more about Entact Bio, visit http://entactbio.com/

Contact:
Victoria Richon, Chief Executive Officer
617-909-7579
https://www.linkedin.com/in/victoria-richon-b6abb2a/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.